After a brief August hiatus, the US IPO calendar started
building again as five companies set pricing terms and kicked off
their investor roadshows. The first to set terms was a major
Mexican bank, Santander Mexico (BSMX), whose proposed $2.8
billion US listing would make it the second largest US IPO of the
year. The resumption in IPO activity came at a time of
increasingly strong performance for US IPOs. The 22 IPOs since
May are now up an average of 31% from their offer prices,
compared to 18% just two weeks ago, and the average aftermarket
return is up to 17% from 5% two weeks ago. Of the 22 deals, 19
are trading above their offer prices (86% vs. 61% year-to-date).
This favorable trading backdrop, combined with a spate of filings
in August (17, the 2nd highest total year-to-date) and an already
large backlog, could set the stage for a busy end to 2012.
Deal sizes remain small
Other than Santander Mexico, which is being spun off from Spain's
Banco Santander, each of the new IPOs plans to raise less than
$100 million, continuing the trend of smaller deal sizes in 2012
(49% have raised $100 million or less vs. 33% in 2011). Smith
Electric Vehicles, which manufactures commercial electric
vehicles in the US and Europe, is seeking $76 million. The
remaining three were previously confidential filers: Real estate
listings company Trulia and biotechs GlobeImmune and Regulus
Therapeutics hope to raise $90 million, $60 million and $50
million, respectively.
Companies that set terms this week
|
Company (Ticker)
|
Business
|
Deal Size
($mm)
|
Pricing Date
|
Grupo Financiero
Santander Mexico (BSMX) |
Second-largest bank
in Mexico |
$2,785 |
Week of 9/24 |
| Trulia (TRLA) |
Online residential real
estate listings |
$90 |
Week of 9/17 |
| Smith Electric Vehicles (
SMTH
) |
Manufactures commercial
electric vehicles |
$76 |
Week of 9/17 |
| GlobeImmune (
GBIM
) |
Developing treatments for
pancreatic cancer and
hepatitis |
$60 |
Week of 9/17 |
| Regulus Therapeutics (RGLS) |
Developing drugs that
target microRNA |
$50 |
TBA |
US IPO Index outperforms in August
The strong returns this week were a continuation of high
aftermarket returns in August. The FTSE Renaissance US IPO Index
outperformed last month with a return of +3% (Russell 3000; +2%).
Strong index returns were largely attributable to strength in the
consumer goods sector. Global luxury fashion brand Michael Kors (
KORS
) was one of the index’s best performers in August (31%
return) after the company reported exceptionally strong earnings.
Several technology companies also made strong contributions to
index returns in August, including flash storage vendor Fusion-io
(+47%), Chinese mobile security provider Qihoo 360 Technology
(+52%), and global chip manufacturer NXP Semiconductors
(+15%).
Two top performing IPOs report next week
Next week, two of the summer's best performing IPOs will face
high expectations in their first earnings reports as public
companies. Network security company Palo Alto Networks (
PANW
), which is up 68% from its offer price, and discount retailer
Five Below (
FIVE
), which is up 108%, both rose 10% this week and will both report
after the close on Monday. Both companies are trading at
meaningful valuation premiums to their public peers, largely
reflecting investors' hunger for outsized growth.
Only one company added to the pipeline
Only one company, Intercept Pharmaceuticals (ICPT), filed this
week, ending a recent surge in pipeline activity. For the first
time since the passage of the JOBS Act, the public US IPO
pipeline rose last month to 149. More than half of the month's 17
filings came from previously confidential filers, which could
move forward quickly. Friday's launches by Trulia and Regulus
came exactly 21 days after their first public filings, which is
the minimum amount of time required under the JOBS Act. Given the
rumored activity among confidential filers, however, we suspect
more new filings to emerge in the coming weeks (e.g., MGM and
Fairway Market).
US IPO market update
To date, the 91 IPOs in 2012 have gained 19% on average, with
an average aftermarket return of 3%. The US IPO pipeline
currently stands at 150, representing $46.7 billion in estimated
proceeds.